-
<![CDATA[Neulasta Biosimilar Armlupeg FDA Approved to Prevent Infection ]]>
02 Dec 2025 03:22 GMT
… Cyrus Karkaria, president, biotechnology, Lupin, said in … pharmaceutical company that develops branded and generic medicines … , 2022 – FDA Approves Fylnetra Neulasta Biosimilar
Fylnetra ( … receiving myelosuppressive cancer treatment associated with …
-
Lupin Wins FDA Approval for Armlupeg Pegfilgrastim Biosimilar
02 Dec 2025 12:40 GMT
… drug Neulasta®. The approval marks a significant step in the Indian pharmaceutical … complications of cancer treatment, often requiring hospitalization … affordable, high-quality medicines to U.S. … Karkaria, President of Biotechnology at Lupin, called …
-
<![CDATA[FDA Approves Pegfilgrastim-unne for Nonmyeloid Cancers, Febrile Neutropenia]]>
02 Dec 2025 04:49 GMT
… undergoing treatment with myelosuppressive anticancer drugs linked … biosimilar to pegfilgrastim (Neulasta). Pegfilgrastim is used … more affordable, accessible medicines to US patients. … FDA approves Lupin’s Armlupeg injection. News release. Pharmaceutical …
-
Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg - Pegfilgrastim-unne
01 Dec 2025 10:43 GMT
… Food and Drug Administration (U.S. FDA) has approved … reducing barriers to treatment and empowering patients … . Cyrus Karkaria, President, Biotechnology, Lupin.
Pegfilgrastim 6 mg … Bulls
Keywords
Lupin
INE326A01037
Pharmaceuticals
USFDA
Approval
Armlupeg
…
-
Lupin gets U.S. FDA nod for biosimilar
01 Dec 2025 21:59 GMT
… mL injection as biosimilar to Neulasta (pegfilgrastim) 6 mg… biotech facility in Pune, which was inspected by the U.S. FDA … providing more affordable, accessible medicines to U.S. patients. … receiving myelosuppressive anti-cancer drugs associated with a …
-
Lupin gets FDA nod for white blood cell booster Neulasta Biosimilar
01 Dec 2025 12:41 GMT
… Limited has secured US FDA approval for Neulasta (Pegfilgrastim-unne) … doses of radiation
The drug also helps to decrease … receiving myelosuppressive anti-cancer drugs.
As of September this … providing more affordable, accessible medicines to U.S. patients. …
-
US FDA approves Lupin’s Armlupeg injection
01 Dec 2025 10:37 GMT
… Neulasta (pegfilgrastim).
The company will manufacture the product at its biotechnology … undergoing treatment with myelosuppressive anti-cancer drugs … more affordable, accessible medicines to US patients … deserve! The Pharmaceutical Technology Excellence Awards …
-
Lupin gets U.S. FDA Approval for Biosimilar Armlupeg
01 Dec 2025 03:54 GMT
… . FDA clearing its new product Armlupeg™, a biosimilar version of Neulasta … .
The drug will be manufactured at Lupin’s biotech facility in … strong due to rising cancer treatment volumes.
Armlupeg™ is designed … cost efficiencies and expanded treatment access.
-
<![CDATA[FDA Approves Osvyrti and Jubereq in High Fracture Risk Populations, Including in Breast and Prostate Cancer]]>
21 Nov 2025 00:12 GMT
… ustekinumab (Stelara), and pegfilgrastim (Neulasta) respectively.2
“Both Osvyrti and … morbidity, and for the treatment of hypercalcemia in malignant … 1 and phase 3 trials. The phase 1 was … and managing director of Intas Pharmaceuticals, added. “We believe …
-
<![CDATA[IMforte Trial Maintenance Regimen Extends Survival for ES-SCLC]]>
23 Oct 2025 21:17 GMT
… with oncologists about trials of chemoimmunotherapy and additional … essentially prophylactic pegfilgrastim [Neulasta]. That was a … G1 Therapeutics, Genentech, Jazz Pharmaceuticals, Outcomes Insights, EMD Serono … in first-line treatment of extensive-stage …